secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001438533-25-000055
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere reports Q3 net income of $25.7M; FILSPARI sales up 155% YoY to $90.9M
-----------------------------------------------------------------------------

- U.S. FILSPARI net product sales $90.9M (+155% YoY); 731 new patient start forms in Q3.
- Total revenue $164.9M incl. $40M milestone from CSL Vifor; net income $25.7M ($0.29 basic EPS) vs net loss of $54.8M in Q3 2024.
- Remaining $68.9M of 2025 convertible notes retired; cash & equivalents $254.5M as of Sep 30 (excl. October milestone).
- FDA sNDA for FILSPARI in FSGS under review; PDUFA target Jan 13, 2026; no advisory committee needed.
- REMS modified removing embryo-fetal toxicity monitoring; KDIGO guidelines recommend FILSPARI as first-line therapy in IgAN.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000055/0001438533-25-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000055/tvtx-20251030.htm
  HTML page:      https://secwatch.observer/filing/0001438533-25-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer